CD38 and plasma cell myeloma: In comparison, incorporation of daratumumab, an anti-CD38 monoclonal antibody, represents a more promising therapeutic approach in combination with lenalidomide and dexamethasone, given its balance of tolerability and efficacy in both patients with multiple myeloma and POEMS.